Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 91

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 91
---
 customary closing conditions. The Fifth Securities
Purchase Agreement includes the consent of the holders of the Company’s outstanding Series C and Series D convertible preferred
stock to the issuance of the Series E Preferred Stock pari passu therewith, in consideration for the reduction of the conversion
price for the Company’s outstanding Series C and Series D convertible preferred stock to $1.76, effective as of the date of the
Fifth Securities Purchase Agreement.

Nasdaq Notices of Non-compliance and Nasdaq Panel Decision

As previously disclosed,
on January 17, 2025, the Company received a letter setting forth the determination of a panel convened by Nasdaq (the “Nasdaq Panel”)
granting the Company’s request for an extension (the “Extension”) to regain compliance with certain continued listing
requirements of the Nasdaq Stock Market until April 22, 2025. The Company presented its plan (the “Plan”) for regaining compliance
with such requirements at a hearing conducted on December 17, 2025. The Company’s Plan included completion of a reverse stock split,
which occurred on January 8, 2025, and transferring the listing of its securities to the Nasdaq Capital Market, which was completed on
February 12, 2025, and certain other conditions, including the satisfaction of the $2.5 million minimum stockholders’ equity requirement
for continued listing on the Nasdaq Capital Market.

In addition, as previously
disclosed, from November 2024 through September 30, 2025, the Company raised approximately $4.4 million of net proceeds from its equity
line of credit entered into November 2024, and an additional approximately $4.2 million of net proceeds from its public offering of shares
of common stock, pre-funded warrants and warrants to purchase shares of common stock that closed on February 7, 2025 (the “February
2025 Offering”). As a result of such capital raising activities and the proceeds of the Private Placement received on the First
Closing Date, as well as successful negotiations with certain service providers to reduce outstanding balances payable, the Company received
a notification letter from Nasdaq on May 7, 2025, stating that the Company had regained compliance with the Nasdaq continued listing standard
under Nasdaq Listing Rule 5550(b)(1), which requires, among other things, that the Company maintain at least $2.5 million in stockholders’
equity.

<div align='center'>36</div>